Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

PubWeight™: 4.49‹?› | Rank: Top 1%

🔗 View Article (PMID 32205204)

Published in Int J Antimicrob Agents on March 20, 2020

Authors

Philippe Gautret1, Jean-Christophe Lagier2, Philippe Parola1, Van Thuan Hoang3, Line Meddeb4, Morgane Mailhe4, Barbara Doudier4, Johan Courjon5, Valérie Giordanengo6, Vera Esteves Vieira4, Hervé Tissot Dupont2, Stéphane Honoré7, Philippe Colson2, Eric Chabrière2, Bernard La Scola2, Jean-Marc Rolain2, Philippe Brouqui2, Didier Raoult8

Author Affiliations

1: IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
2: IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
3: IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam.
4: IHU-Méditerranée Infection, Marseille, France.
5: Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France; Université Côte d'Azur, Nice, France; U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Virulence Microbienne et Signalisation Inflammatoire, INSERM, Nice, France.
6: Department of Virology, Biological and Pathological Center, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.
7: Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
8: IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: Didier.raoult@gmail.com.

Associated clinical trials:

A Study of Quintuple Therapy to Treat COVID-19 Infection (HAZDpaC) | NCT04334512

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19) | NCT04335084

Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial (AZIQUINE-ICU) | NCT04339816

Will Hydroxychloroquine Impede or Prevent COVID-19 (WHIP COVID-19) | NCT04341441

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia (CCAP) | NCT04345289

Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19 | NCT04349592

Trial of Hydroxychloroquine In Covid-19 Kinetics (THICK) | NCT04353271

Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm | NCT04355247

Convalescent Plasma Trial in COVID -19 Patients | NCT04356534

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 | NCT04361318

Observational Cohort of COVID-19 Patients at Raymond-Poincare (COVID-RPC) | NCT04364698

OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV) | NCT04365582

Observational Study of COVID-19 Treatment Efficacy | NCT04369989

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting | NCT04370782

COVID-19 - Quality of Life After Infection | NCT04377464

Favipiravir vs Hydroxychloroquine in COVID -19 | NCT04387760

Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection | NCT04391127

Trial of Imatinib for Hospitalized Adults With COVID-19 | NCT04394416

Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) (PREVICHARM) | NCT04400019

Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients | NCT04443270

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression (COVID-19) | NCT04491994